TENOFOVIR (TFV) ALAFENAMIDE (TAF) DOSE IN THE FIRST PIBASED SINGLE TABLET REGIMEN (STR) DARUNAVIR/COBICISTAT/EMTRICITABINE/TAF (DRV/COBI/FTC/TAF; D/C/F/TAF).

被引：0
|
作者：
Custodio, J. M. [1 ]
Wei, X. [1 ]
Wang, H. [1 ]
Hepner, M. [1 ]
Zack, J. Z. [1 ]
Callebaut, C. [1 ]
McCallister, S. [1 ]
Miller, M. [1 ]
Kearney, B. P. [1 ]
Ramanathan, S. [1 ]
机构：
[1] Gilead Sci Inc, Foster City, CA 94404 USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2015年 / 97卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PI-052
引用
收藏
页码：S36 / S36
页数：1
相关论文
共 50 条
  • [21] Efficacy and Safety of Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide (E/C/F/TAF) in Virologically Suppressed Women Text
    Hodder, Sally
    Squires, Kathleen
    Kityo, Cissy
    Hagins, Debbie
    Avihingsanon, Anchalee
    Kido, Anna
    Jiang, Shuping
    Kulkarni, Rima
    Cheng, Andrew
    Cao, Huyen
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2018, 78 (02) : 209 - 213
  • [22] Modelling the long-term clinical outcomes of the novel single-tablet regimen bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in the UK
    Hearmon, N.
    Matin, N.
    Painter, C.
    Robinson, C.
    Eddowes, L.
    Kearns, S.
    Jandu, S.
    Wild, L.
    [J]. HIV MEDICINE, 2019, 20 : 21 - 21
  • [23] Real-life experience with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in a single centre in Portugal
    Gorgulho, A.
    Vaz-Pinto, I.
    Santos, C.
    Guimaraes, M.
    Castro, V.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 103 - 104
  • [24] A combination regimen by lopinave/litonawe (LPV/r), emtricitabine and tenofovir alafenamide fumarate (FTC/TAF) for treatment of novel coronavirus pneumonia (TARCoV)
    Jiang Hua
    Wang Yu
    Wang Kai
    Yang Xingxiang
    Zhang Jiancheng
    Deng Hongfei
    Wang Lu
    Zeng Jun
    [J]. 中华急诊医学杂志, 2020, (03) : E006 - E006
  • [25] Efficacy and Safety of Co-formulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide (E/C/F/TAF) in the Geriatric Adult with Renal Impairment
    Martorell, C.
    Ward, D.
    Short, W. S.
    Ramgopal, M.
    Das, M.
    Nguyen-Cleary, T.
    Shave, A.
    McCallister, S.
    [J]. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2017, 65 : S177 - S177
  • [26] Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-naive (AMBER) and virologically suppressed (EMERALD) patients with neurologic and/or psychiatric comorbidities: Week 96 subgroup analysis
    Bushen, J.
    Luo, D.
    Simonson, R. B.
    Burress, R.
    Brown, K.
    Anderson, D.
    Dunn, K.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 111 - 112
  • [27] Low Incidence and Brief Duration of Gastrointestinal Adverse Events with Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Over 96 Weeks: Post hoc Analyses of AMBER and EMERALD
    Dunn, Keith
    Baugh, Bryan
    Bejou, Nika
    Luo, Donghan
    Campbell, Jennifer
    Seyedkazemi, Sareh
    Anderson, David
    [J]. JOURNAL OF THE INTERNATIONAL ASSOCIATION OF PROVIDERS OF AIDS CARE, 2022, 21
  • [28] Relative Bioavailability of Dolutegravir (DTG) and Emtricitabine/Tenofovir Alafenamide Fumarate (F/TAF) Administered as Paediatric Tablet Formulations in Healthy Volunteers
    Bevers, Lisanne A. H.
    Kamphuis, Anne E. M.
    van der Wekken-Pas, L. C. Wendy
    Leisegang, Rory
    Burger, David M.
    Colbers, Angela
    [J]. CLINICAL PHARMACOKINETICS, 2024, 63 (05) : 721 - 728
  • [29] Week 48 Resistance Analyses of the Once-Daily, Single-Tablet Regimen Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Adults Living with HIV-1 from the Phase III Randomized AMBER and EMERALD Trials
    Lathouwers, Erkki
    Wong, Eric Y.
    Brown, Kimberley
    Baugh, Bryan
    Ghys, Anne
    Jezorwski, John
    Mohsine, El Ghazi
    Van Landuyt, Erika
    Opsomer, Magda
    De Meyer, Sandra
    De Wit, S.
    Florence, E.
    Vandekerckhove, L.
    Vandercam, B.
    Brunetta, J.
    Klein, M.
    Murphy, D.
    Rachlis, A.
    Walmsley, S.
    Ajana, F.
    Cotte, L.
    Girard, P-M
    Katlama, C.
    Molina, J-M
    Poizot-Martin, I
    Raffi, F.
    Rey, D.
    Reynes, J.
    Teicher, E.
    Yazdanpanah, Y.
    Arasteh, K.
    Bickel, M.
    Bogner, J.
    Esser, S.
    Faetkenheuer, G.
    Jessen, H.
    Kern, W.
    Rockstroh, J.
    Spinner, C.
    Stellbrink, H-J
    Stoehr, A.
    Antinori, A.
    Castelli, F.
    Chirianni, A.
    De Luca, A.
    Di Biagio, A.
    Galli, M.
    Lazzarin, A.
    Maggiolo, F.
    Maserati, R.
    [J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 2020, 36 (01) : 48 - 57
  • [30] Switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat in heavily antiretroviral-experienced, virologically suppressed HIV-infected adults receiving complex regimens
    Podzamczer, Daniel
    Imaz, Arkaitz
    Lopez-Lirola, Ana
    Knobel, Hernando
    Masia, Mar
    Fanciulli, Chiara
    Hernandez, Cristina
    Lagarde, Maria
    Gutierrez, Angela
    Curran, Adria
    Morano, Luis
    Montero-Alonso, Marta
    Troya, Jesus
    Rigo, Raul
    Casadella, Maria
    Navarro-Alcaraz, Antonio
    Ardila, Fernando
    Parera, Mariona
    Bernal, Enrique
    Echeverria, Patricia
    Estrada, Vicente
    Hidalgo-Tenorio, Carmen
    Macias, Juan
    Prieto, Paula
    Portilla, Joaquin
    Valencia, Eulalia
    Vivancos, Maria Jesus
    Rivero, Antonio
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2023, 78 (11) : 2696 - 2701
12345